DNLI
Denali Therapeutics Inc
20.50$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.8% | -0.7% | -10.2% | -5.4% | +0.8% | +73.3% | -5.2% | -3.2% | +28.3% | -0.6% | -29.5% | – | |
| – | -5.4% | +7.1% | -9.8% | -1.0% | +0.9% | +0.3% | +0.9% | -1.0% | -4.7% | -3.6% | -0.7% | – | |
| – | – | -370.3% | – | – | -65.2% | -307.8% | – | -126.7% | – | -648.2% | – | – | |
| – | +8.1% | -3.8% | +122.6% | -18.8% | +31.1% | -0.3% | -15.8% | -67.8% | +10.6% | +61.8% | -67.4% | – | |
| – | -27.6% | -720.4% | – | -5.0% | +83.9% | -89.1% | +742.4% | -63.4% | -64.1% | +354.8% | -210.2% | – | |
| – | – | – | – | – | -65.3% | -47.7% | -44.1% | -44.1% | -98.8% | +6.3% | +23.5% | – | |
| – | +88.8% | +10,532.8% | -98.6% | -374.7% | -77.5% | -9.7% | – | -147.9% | – | +14.0% | -93.2% | – | |
| – | -230.3% | – | – | +13.1% | +428.4% | -238.1% | – | -159.6% | – | +59.4% | -202.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.